Related Experiment Videos
Prospects for the prevention of stroke
1Sahlgrenska University Hospital/Ostra, Göteborg, Sweden. bdahlof@scri.se
Summary
Angiotensin II receptor blockers (ARBs) offer stroke prevention benefits beyond blood pressure control. Studies like LIFE and MOSES show ARBs reduce stroke incidence, LVH, and other conditions, with telmisartan showing promise.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Stroke represents a significant epidemic, necessitating novel treatment strategies.
- Blood pressure control is crucial, but specific antihypertensive therapies, such as renin-angiotensin system blockers, are also vital.
- Left ventricular hypertrophy (LVH) is a common comorbidity in hypertensive patients.
Purpose of the Study:
- To evaluate the benefits of angiotensin II receptor blockers (ARBs) beyond blood pressure reduction in hypertension management.
- To assess the efficacy of ARBs in preventing stroke and other cardiovascular events.
- To explore the potential of specific ARBs, like telmisartan, in stroke prevention.
Main Methods:
- Review of clinical trial data, including the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, Study on COgnition and Prognosis in the Elderly (SCOPE), and MOrbidity and mortality after Stroke, Eprosartan compared with nitrendipine in Secondary prevention (MOSES) trial.
- Analysis of experimental findings and clinical evidence supporting ARB benefits in stroke prevention.
- Consideration of telmisartan's pharmacological profile, including its 24-hour efficacy and peroxisome proliferator-activated receptor-gamma activity.
Main Results:
- The LIFE study demonstrated that losartan-based therapy led to LVH regression and significantly reduced stroke incidence, new-onset diabetes, and atrial fibrillation compared to atenolol.
- The MOSES trial indicated clear benefits of ARBs independent of blood pressure lowering in secondary stroke prevention.
- Evidence suggests ARBs provide advantages beyond mere blood pressure reduction.
Conclusions:
- ARBs represent a valuable therapeutic class for stroke prevention, offering benefits beyond blood pressure control.
- Specific ARBs, such as telmisartan, possess unique properties that may enhance stroke prevention, particularly in secondary prevention settings.
- Further research, like the PRoFESS study, is investigating the role of agents like telmisartan in preventing recurrent strokes.